Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Diet Suppl ; 15(3): 300-310, 2018 May 04.
Article in English | MEDLINE | ID: mdl-28759296

ABSTRACT

The purpose of this study was to illustrate the effects of zinc oxide nanoparticles (ZnO-NPs) administration on bone turnover and bone resorbing agents in rats and how L-arginine (L-arg) or vitamin E (vit E) co-administrations might affect them. Fasting rats were randomly divided into four groups (n = 10): G1-normal healthy animals; G2-ZnO-NPs-exposed rats (600 mg/kg-1/day-1); G3-ZnO-NPs-exposed rats co-administrated L-arg (200 mg/kg-1/day-1); G4-ZnO-NPs-exposed rats co-administrated vit E (200 mg/kg-1/day-1). The ingredients were orally administered daily. The body weight and food consumption of rats were recorded during the administration period and the experiment continued for three consecutive weeks. The results demonstrated that ZnO-NPs administration induced bone loss in rats as manifested by reduced activity of bone alkaline phosphatase (B-ALP) and increased level of C-terminal peptide type I collagen (CTx). The increase of inflammatory markers, tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by ZnO-NPs suggests that deleterious effects of ZnO-NPs on bone turnover were, in part, due to inflammation. Confirming to this suggestion, both L-arg and vit E reduced TNF-α and IL-6 levels and consequently decreased bone resorption as indicated by reduced serum CTx level. This study proved that ZnO-NPs can induce bone turnover, which may be reduced by L-arg or vit.E co-administration, partly by anti-inflammatory mechanism.


Subject(s)
Arginine/therapeutic use , Dietary Supplements , Metal Nanoparticles/toxicity , Osteoporosis/prevention & control , Protective Agents/therapeutic use , Vitamin E/therapeutic use , Zinc Oxide/toxicity , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/therapeutic use , Biomarkers/blood , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Bone and Bones/drug effects , Bone and Bones/immunology , Environmental Pollutants/administration & dosage , Environmental Pollutants/antagonists & inhibitors , Environmental Pollutants/toxicity , Inflammation Mediators/blood , Metal Nanoparticles/administration & dosage , Metal Nanoparticles/chemistry , Osteitis/blood , Osteitis/chemically induced , Osteitis/immunology , Osteitis/prevention & control , Osteoporosis/blood , Osteoporosis/chemically induced , Osteoporosis/immunology , Random Allocation , Rats, Wistar , Zinc Oxide/administration & dosage , Zinc Oxide/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL